Core Viewpoint - ST Zhongzhu announced new developments in a contract dispute involving its subsidiary Yiti Medical and Puyang Fifth Hospital, with the case amounting to 32.7035 million yuan [1] Summary by Relevant Sections - **Legal Proceedings** - Yiti Medical received a second-instance civil ruling from Puyang Intermediate Court on November 29, 2025, regarding the contract dispute [1] - The first-instance ruling had annulled the cooperation agreement and rejected other claims from Yiti Medical, which led to an appeal [1] - Puyang Intermediate Court found that the basic facts of the first-instance ruling were unclear, thus revoking the original judgment and sending the case back for retrial [1] - **Financial Implications** - The case involves a disputed amount of 32.7035 million yuan [1] - Yiti Medical has been refunded the prepayment of 200,200 yuan for the second-instance handling fee due to the retrial [1] - The company has stated that it is currently unable to confirm the impact on its profits due to the ongoing retrial and will disclose further developments in a timely manner [1]

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for the sector in the next 6-12 months [9][63]. Core Insights - The medical services sector has shown resilience, with a recent performance boost attributed to the seasonal increase in flu cases, despite ongoing cost control pressures from medical insurance [9][63]. - The report highlights the significance of the recent government initiative to promote provincial-level medical insurance coordination, which is expected to enhance the efficiency of fund utilization and improve the overall healthcare system [5][6][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 31.62, with a Price-to-Book (PB) ratio of 3.18, indicating a slight increase from the previous week [4][29]. Summary by Sections Industry Performance - The pharmaceutical and biological sector experienced a decline of 2.67% this week, ranking 17th among 31 primary industries [2][11]. - The medical services sub-sector reported a slight increase of 1.42%, closing at 6237.83 points [22][23]. Company Performance - Top-performing companies in the medical services sector include ST Zhongzhu (+16.3%), Baihua Pharmaceutical (+11.6%), and Lanwei Medical (+10.6%) [3][27]. - Underperforming companies include Aier Eye Hospital (-1.6%) and WuXi AppTec (-0.7%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.40 from the previous week, while the PB ratio has risen by 0.04 [4][29]. - The maximum and minimum PE ratios over the past year were 41.13 and 28.46, respectively, indicating a relatively stable valuation range [4][29]. Government Policy Impact - The recent government meeting emphasized the importance of provincial-level medical insurance coordination, which aims to balance fund distribution across regions and enhance the overall healthcare system [5][6][61]. - The report identifies structural opportunities for the pharmaceutical industry, particularly in innovative drugs, medical devices, and healthcare information technology, as a result of the new insurance policies [6][62]. Investment Recommendations - The report suggests focusing on high-growth areas such as pharmaceutical outsourcing services and companies with improving profit margins, including WuXi AppTec and Aier Eye Hospital [9][63].

证券代码：600568 证券简称：ST 中珠 公告编号：2025-064 号 中珠医疗控股股份有限公司 关于股票交易风险提示公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）股票价格近期存 在大幅波动的风险，敬请广大投资者审慎理性决策，注意二级市场交易风险。现提示重 要内容如下： 一、关于公司第一大股东之股东股权发生变化的风险 2025年11月23日，公司第一大股东深圳市朗地科技发展有限公司（以下简称"朗地 科技"）控股股东深圳市深商控股集团股份有限公司（以下简称"深商控股"）与苏州 步步高投资发展有限公司（以下简称"苏州步步高"）签署了《关于深圳市朗地科技发 展有限公司之股权转让协议》，根据协议，深商控股拟将其持有的朗地科技100%股权转 让给苏州步步高。本次股权转让完成后，朗地科技控股股东由深商控股变更为苏州步步 高。本次权益变动属于公司第一大股东之股东转让股份，不会导致公司第一大股东发生 变化，不触及要约收购，公司无控股股东及实际控制人的情形未发生变 ...

特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）董事会于2025年11月27日收到公司董事武 有先生、独立董事张霞女士送达的书面辞职报告。 武有先生因个人原因，申请辞去公司董事、董事会审计委员会委员、董事会薪酬与考核委员会委员职 务。辞职后，武有先生不再担任公司任何职务。 张霞女士因个人原因，申请辞去公司独立董事、董事会战略委员会委员、董事会审计委员会召集人、董 事会提名委员会委员、董事会薪酬与考核委员会委员职务。辞职后，张霞女士不再担任公司任何职务。 中珠医疗控股股份有限公司 武有先生和张霞女士在公司任职期间恪尽职守、勤勉尽责，本公司及董事会对武有先生和张霞女士在公 司任职期间为公司发展所做出的贡献表示衷心感谢！ 根据《公司法》《公司章程》《上市公司独立董事管理办法》《上海证券交易所上市公司自律监管指引 第1号一一规范运作》等相关规定，武有先生和张霞女士的离任未导致公司董事会成员低于法定最低人 数。 特此公告。 张霞女士的离任将导致公司董事会 ...

中珠医疗控股股份有限公司 关于公司董事、独立董事离任的公告 特别提示 证券代码：600568 证券简称：ST 中珠 公告编号：2025-063 号 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》《公司章程》《上市公司独立董事管理办法》《上海证券交易 所上市公司自律监管指引第 1 号——规范运作》等相关规定，武有先生和张霞女 士的离任未导致公司董事会成员低于法定最低人数。 张霞女士的离任将导致公司董事会中独立董事所占比例少于三分之一，在补 选完成前，张霞女士仍需按照相关法律法规等要求继续履行职责。 武有先生、张霞女士的离任将导致董事会审计委员会成员人数低于法定人数， 在补选完成前，武有先生和张霞女士仍需按照相关法律法规等要求继续履行职责。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）董事会于 2025年11月27日收到公司董事武有先生、独立董事张霞女士送达的书面辞职报告。 武有先生因个人原因，申请辞去公司董事、董事会审计委员会委员、董事会 薪酬与考核委员会委员职务。辞职后，武有先生不再担任公司任何职 ...

南财智讯11月27日电，ST中珠公告，公司董事会于2025年11月27日收到公司董事武有、独立董事张霞 送达的书面辞职报告。武有因个人原因，申请辞去公司董事、董事会审计委员会委员、董事会薪酬与考 核委员会委员职务。辞职后，武有不再担任公司任何职务。张霞因个人原因，申请辞去公司独立董事、 董事会战略委员会委员、董事会审计委员会召集人、董事会提名委员会委员、董事会薪酬与考核委员会 委员职务。辞职后，张霞不再担任公司任何职务。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600568 | ST中珠 | 2.58 | -4.44% | 150.64万 | 3.98亿 | | 920670 | 数字人 | 16.36 | -3.76% | 5.32万 | 8826.15万 | | 603259 | 药明康德 | 92.20 | -3.23% | 50.61万 | 46.68 Z | | 300244 | 迪安诊断 | 15.76 | -2.96% | 17.23万 | 2.75亿 | | 301201 | 诚达药业 | 45.75 | -2.62% | 10.39万 | 4.81亿 | | 603882 | 金域医学 | 29.27 | -2.04% | 5.78万 | 1.70亿 | | 301060 | 兰卫医学 | 10.58 | -1.95% | 27.70万 | 2.93亿 | | 002044 | 美年健康 | 5.28 | -1.68% | 71.98万 | 3.82亿 | | 688131 | 皓元医药 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 上市公司名称：中珠医疗控股股份有限公司 股票上市地点：上海证券交易所 股票简称：ST中珠 股票代码：600568 信息披露义务人：深圳市深商控股集团股份有限公司 住所：深圳市南山区粤海街道麻岭社区科技中三路1号海王银河科技大厦20层 股份变动性质：股份减少（间接方式转让） 一、信息披露义务人根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收购管理办法》"）、 《公开发行证券的公司信息披露内容与格式标准第15号---权益变动报告书》（以下简称"《准则第15 号》"）及相关法律、法规和规范性文件编写本报告书。 二、本信息披露义务人签署本报告已获得必要的授权和批准，其履行亦不违反信息披露义务人章程或内 部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购管理办法》《准则第15号》的规定，本报告书已全面披露信息披露义务人在 中珠医疗控股股份有限公司中拥有权益的股份变动情况。 四、截至本报告书签署日，除本报告书披露的信息外，信息披露义务人没有通过任何其他方式增加或 ...

Group 1 - ST Zhongzhu announced the receipt of a share transfer agreement from Shenzhen Shenshang Holdings Group, where Shenshang plans to transfer 100% equity of its major shareholder, Shenzhen Landi Technology, to Suzhou Bubugao Investment Development for 30 million yuan [1] - After the transfer, Bubugao Investment will hold 380,172,862 shares of ST Zhongzhu, representing 19.08% of the total share capital [1] - Bubugao Investment stated that there are no plans to increase or decrease its stake in the company within the next 12 months, nor are there any major asset restructuring plans [1] Group 2 - On November 14, ST Zhongzhu announced that Qiongcheng Meihua Tenglong Qifei Investment Partnership intends to acquire 10.38% of the company's shares for 403 million yuan [2] - Qiongcheng Meihua Tenglong Qifei Investment Partnership, which is 80% owned by Wu Shichun, expressed confidence in the company's future development prospects and investment value [2] - The partnership aims to actively exercise shareholder rights to improve the company's operations, asset quality, and sustainable profitability [2]

Group 1 - ST Zhongzhu (sh600568) hit the daily limit down on November 27, 2025, with a closing price of 2.57 yuan, a decline of 4.07%, and a total market capitalization of 5.162 billion yuan [1] - The stock experienced a total trading volume of 113 million yuan by the time of reporting [1] Group 2 - The reasons for ST Zhongzhu's limit down include capital outflow, sector pressure, and declining concept heat: 1. Capital outflow pressure: On November 25, 2025, the stock's sell amount exceeded the buy amount, indicating some capital was leaving the market, which could negatively impact the stock price [2] 2. Poor sector performance: The overall underperformance of the healthcare services sector can exert pressure on ST Zhongzhu's stock price, as it is related to this sector [2] 3. Declining concept heat: Although the stock attracted market attention with the new "yesterday's consecutive board" concept on November 14, 2025, the excitement may have waned over time, leading to reduced buying interest and upward momentum [2] 4. Technical and capital influences: Recent capital flow trends show an outflow, and technical indicators such as MACD crossovers and BOLL channel breaches may exacerbate bearish market sentiment, contributing to the limit down [2]